Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Study to Investigate the Influence of PTH-lowering by Etelcalcetide (Parsabiv®) on the Calcification Propensity of Serum in Dialysis Patients

NCT03795558 is registered in ClinicalTrials.gov with Prim. Priv. Doz. Dr. Daniel Cejka as lead sponsor.

NCT NCT03795558
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03795558 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Study to Investigate the Influence of PTH-lowering by Etelcalcetide (Parsabiv®) on the Calcification Propensity of Serum in Dialysis Patients
Lead sponsor
Prim. Priv. Doz. Dr. Daniel Cejka
Phase
Phase 2
Overall status
Completed
Start date
May 1, 2019
Completion date
March 1, 2022
Enrollment
37 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

end stage renal disease